Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Chimeric Antigen Receptor (CAR) T Cells”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Early research (Phase 1)UnknownNCT03271515
What this trial is testing

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Who this might be right for
LeukemiaLymphoma
Beijing Doing Biomedical Co., Ltd. 20
Very early researchNot Yet RecruitingNCT07546630
What this trial is testing

Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory B-Cell Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences 20
Not applicableStudy completedNCT06415656
What this trial is testing

VitalTraq for the Detection of CRS

Who this might be right for
Hematologic Malignancy
Duke University 32
Very early researchUnknownNCT04303247
What this trial is testing

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Who this might be right for
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Xinqiao Hospital of Chongqing 30
Early research (Phase 1)Looking for participantsNCT06285279
What this trial is testing

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Who this might be right for
Lupus NephritisANCA-associated VasculitisMembranous Nephropathy - PLA2R Induced+1 more
Nanjing University School of Medicine 24
Early research (Phase 1)Looking for participantsNCT06559189
What this trial is testing

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver 53
Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06735495
What this trial is testing

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)UnknownNCT04303520
What this trial is testing

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Who this might be right for
CD19-positive ALL
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Early research (Phase 1)Looking for participantsNCT07193628
What this trial is testing

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

Who this might be right for
Refractory GlioblastomaRecurrent Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT07461831
What this trial is testing

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)
Beijing Tongren Hospital 100
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Not applicableLooking for participantsNCT07309497
What this trial is testing

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich 208
Early research (Phase 1)UnknownNCT04662099
What this trial is testing

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

Who this might be right for
CS1+ or BCMA+ Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04499573
What this trial is testing

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

Who this might be right for
B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 50
Early research (Phase 1)Not Yet RecruitingNCT07335328
What this trial is testing

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Who this might be right for
B-cell Non Hodgkin Lymphoma
Medical College of Wisconsin 24
Early research (Phase 1)Looking for participantsNCT05098613
What this trial is testing

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Who this might be right for
Non-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma (B-NHL)Mantle Cell Lymphoma (MCL)+1 more
University of Colorado, Denver 68
Early research (Phase 1)WithdrawnNCT05950113
What this trial is testing

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Load More Results